A convenient once-daily oral treatment option for the treatment of moderate-to-severe atopic dermatitis (AD)1
  • For patients aged 18 years and older
  • A treatment that includes an indication for itch relief
  • For patients who are uncontrolled on or cannot use Rx topicals
Mechanism of disease video
Learn more about why the JAK/STAT pathway is believed to be an important mediator of the pathophysiology of AD​​​​​​​2
JAK=Janus kinase; STAT=signal transducer and activator of transcription.​​​​​​​
Mechanism of action video
Learn more about the mechanism of action of CIBINQO and how it works inside the cell to inhibit JAK1​
References: 1. CIBINQO™ (abrocitinib) Full Prescribing Information. April 2021. 2. Clark JD, Flanagan ME, Telliez JB. Discovery and development of Janus kinase (JAK) inhibitors for inflammatory diseases. J Med Chem. 2014;57(12):5023-5038.
Start Guide
Ready to get a patient started?

A Convenient Oral

CIBINQO gives you the ability to tailor treatment to meet individual patient goals for efficacy and tolerability

​​​​​​​To report any Adverse Events related to Pfizer pharmaceutical products,
please contact us via the following [email protected]
If you have any medical inquiries about Pfizer pharmaceutical products,
please contact our medical information services: [email protected]

© 2021 Pfizer Pte Ltd. All rights reserved.

The information provided in this site is intended only for Healthcare Professionals in Singapore. The products discussed herein may have different product labelling in different countries. Pfizer Pte Ltd, Singapore is a subsidiary of Pfizer Inc, a pharmaceutical company committed to helping people improve their health by discovering and developing medicines.